04.20.21

Palatin Announces Two Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Source: Palatin

Palatin Technologies announced two presentations of the company’s melanocortin platform, including PL9643 in dry eye disease, at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held virtually May 1-7, 2021.

The presentations highlight the positive clinical data from the phase 2 clinical study in dry eye disease patients, and the possible utility of melanocortins in the treatment of inflammation and, specifically, ocular inflammation. 

“Palatin is excited to present two examples of the significant utility of melanocortins in the treatment for inflammatory conditions. The eye, as well as the gut and kidney, offer a unique environment where melanocortin agonism promotes resolution of inflammation,” Carl Spana, PhD, President and CEO of Palatin, said in a company news release. “ARVO is the premier global eye and vision forum. We are pleased to showcase Palatin’s expertise with melanocortin peptides and how they may provide a safe, well-tolerated, and effective treatment path for inflammatory conditions in the eye.”

The presentation details:

Date:  

May 1, 2021

Time: 

3:15 pm to 4:45 pm Eastern Time

Session Title:

Dry eye clinical treatments

Format:        

Podium Presentation

Presenter:  

Kenneth Kenyon, MD, treating ophthalmologist and primary investigator

Title:  

Efficacy and Safety of the Melanocortin Agonist PL9643 in a Phase 2 Study of Subjects with Dry Eye Disease”

   

Date:

May 6, 2021

Time:

11:15am – 1:00pm Eastern Time

Session Title:  

Stem cells/gene therapy/transplantation/laser/local therapy

Format:               

Poster Presentation

Presenter:

John Dodd, PhD, Senior Vice President of Preclinical Research

Title:

Protective Effects of 2 Melanocortin Agonists Delivered by Intravitreal Injection in Mouse Models of Retinopathy”

Both presentations will be available on the Palatin website, www.palatin.com, after the ARVO annual meeting ends on May 7, 2021.

About Melanocortins and Inflammation

The melanocortin receptor (“MCr”) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects. 

Many tissues and immune cells located in the eye express melanocortin receptors, empowering our opportunity to directly activate natural pathways to resolve disease inflammation.

Related Content